Mersana Therapeutics

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Mersana Therapeutics sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).

11 total trials 2 currently recruiting 5 completed early-phase tilt top decile by trial count

Mersana Therapeutics: 11 sponsored US clinical trials, 2 recruiting.

Mersana Therapeutics sponsors 11 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 5 completed. 1 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Platinum-resistant Ovarian Cancer, with 3 trials.

Top-decile sponsor footprint

Mersana Therapeutics ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

11 total, page 1 of 1

RECRUITING Phase 1

A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

NCT05514717
RECRUITING Phase 1

A Study of XMT-1660 in Participants With Solid Tumors

NCT05377996
ACTIVE NOT RECRUITING Phase 1

First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b

NCT03319628
TERMINATED Phase 3

Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)

NCT05329545
TERMINATED Phase 1

Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian Cancer

NCT04907968
TERMINATED Phase 1

First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b

NCT04396340
COMPLETED Phase 1

First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2b

NCT06517485
COMPLETED Phase 1

First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b

NCT06517433
COMPLETED Phase 1

Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2

NCT02952729
COMPLETED Phase 1

A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors

NCT00455052
COMPLETED Phase 1

A Study of Intravenous XMT-1107 in Patients With Advanced Solid Tumors

NCT01011972

Phase Distribution

PhaseTrial count
Phase 1 10
Phase 3 1

Therapeutic Areas

Platinum-resistant Ovarian Cancer 3
Non Small Cell Lung Cancer Metastatic 2
Primary Peritoneal Cavity Cancer 1
HER2 Low Breast Cancer 1
HER2-positive Tumors 1
HER2-positive Colorectal Cancer 1
HER2-positive Non-Small Cell Lung Cancer 1
HER2-positive Gastric Cancer 1
Non-Small Cell Adenocarcinoma 1
Fallopian Tube Cancer 1

What is open in the Mersana Therapeutics pipeline

2 recruiting of 11 indexed (18% open); 5 completed (45%).

Phase mix: 1 late (III/IV) vs 10 early (I/II) (early-phase heavy).

Top condition: Platinum-resistant Ovarian Cancer (3 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Mersana Therapeutics: open-pipeline peers nationwide

Peers matched on 11 registered trials and 18% open enrollment, not the therapeutic-area sidebar.

Mersana Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 10.910.91111.1 0%5%10%15%20% Total trials Recruiting share Mersana TherapeuticsAderans Research InstituteAegerion PharmaceuticalsAllena PharmaceuticalsAOBiomeBurke Medical Research InstituteGrand Valley State UniversityImunonInventisBio Co.
Mersana Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Mersana Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 11 trials (± recruiting share)

Sponsors near 18% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Mersana Therapeutics page

11 registered trials is a research-attention snapshot, not an endorsement of Mersana Therapeutics or any single study.

  • 2 of Mersana Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Platinum-resistant Ovarian Cancer is the condition Mersana Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Platinum-resistant Ovarian Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Mersana Therapeutics pipeline card: 11 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.